Invitation to presentation of Immunovia´s interim report January-September 2018 on November 7, 2018
Lund (Sweden) - Immunovia will publish the company’s interim report for the period January-September 2018 on Wednesday, November 7, at 08:30 a.m. CET.
Immunovia invites to a teleconference (in English) for investors, analysts and media on November 7, at 4:30 – 5:30 p.m. CET. Mats Grahn, CEO will present Immunovia and comment on the interim report followed by a Q&A-session.
Please call in a few minutes in advance. To attend, please dial-in at one of the numbers below from:
Telephone:
SE: +46856642662
CH: +41225675548
DE: +4969222229046
DK: +4582333178
FR: +33170750712
UK: +442030089803
NO: +4723500254
US: +16465025116
BE: +3224040635
NL: +31207168416
There will be an MP3-file available at Immunovia’s webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
For questions or interview bookings: ir@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Tags: